Johnson & Johnson has announced Phase 3 results for ICOTYDE (icotrokinra), an oral peptide, in biologic-naive adults with active psoriatic arthritis. The company says the ICONIC-PsA 1 trial met its primary endpoint at Week 16, with results presented as a late-breaking poster at ACR Convergence 2026.

Icotrokinra is a once-daily tablet that J&J describes as the first and only targeted oral peptide designed to block the IL-23 receptor, the signaling pathway behind much of the inflammation in psoriatic disease. That matters mainly because the IL-23 category has until now meant injections, and a peptide small enough to survive a pill is the interesting engineering story here, separate from the efficacy numbers.

Key results

At Week 16, 58% of patients on icotrokinra 200 mg achieved an ACR20 response, compared with 41% on placebo. ACR50 was reached by 29% versus 16%, and ACR70 by 13% versus 5%, both described by the company as numerically higher rather than formally significant.

Among patients with qualifying skin involvement, 57% on icotrokinra reached clear or almost clear skin on the Investigator's Global Assessment, against 14% on placebo, with a nominal p value below 0.001. Response rates continued to rise numerically through Week 24, when 69% had an ACR20 response and 56% had reached PASI 90.

What ACR20 actually measures

ACR20 is a composite: at least a 20% improvement in tender and swollen joint counts plus three of five other disease activity measures. It is the standard entry-level endpoint in rheumatology trials, which is worth remembering when a 58% response rate is read as 58% of people getting better in any plain-language sense.

Limitations

These are company-announced results from a poster, not a peer-reviewed publication, and the placebo group crossed over to active treatment at Week 16, so the Week 24 figures have no placebo comparator. The rheumatologist quoted in the release, Joseph Merola, is disclosed as a paid consultant to Johnson & Johnson, and the ACR50, ACR70 and skin endpoints are reported as numerical or nominal rather than formally tested.

Bottom line

ICOTYDE is approved in the U.S. for moderate-to-severe plaque psoriasis but is not approved for psoriatic arthritis, and the company says so plainly in its own footnotes. A second trial, ICONIC-PsA 2, is running in biologic-experienced patients, and that is where the harder test sits.